CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators - The RAID Trial Baseline Features of the VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) Trial Association Between Functional Impairment and Medication Burden in Adults with Heart Failure Association of Prior Left Ventricular Ejection Fraction With Clinical Outcomes in Patients With Heart Failure With Midrange Ejection Fraction Lifestyle Modifications for Preventing and Treating Heart Failure The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction

Original Research2021 Jun 12;cvab202.

JOURNAL:Cardiovasc Res. Article Link

AIM2-driven inflammasome activation in heart failure

Z Onódi, M Ruppert, D Kucsera et al. Keywords: canakinumab; cardiomyopathy; drug repurposing; heart failure; inflammation; probenecid

Full Text PDF